IGF::OT::IGF METABOLOMICS OF CHD IN THE WHI

WHI 中 CHD 的 IGF::OT::IGF 代谢组学

• 批准号: 9042184
• 负责人: N/A N/A
• 金额: $ 40.41万
• 依托单位: BRIGHAM AND WOMEN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-03-29 至 2016-03-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9042184
• 关键词: Biological Markers; Clinical; Contractor; Coronary heart disease; Data; Estrogens; Genomics; Individual; Measures; Metabolic; Placebo Control; Progesterone; Risk; Testing; Therapy trial; Woman; Women' s Health; hormone therapy; metabolomics

The contractor will measure a well-validated metabolomic profile and test specific metabolic hypotheses for incident Coronary Heart Disease (CHD). In addition, the contractor will examine how Hormone Therapy (HT) changes metabolomic profiles and whether these changes explain the increased risk observed for combined HT in the Women’s Health Initiative (WHI) HT trial.

承包商将测量经过充分验证的代谢组谱，并测试发生冠心病(CHD)的特定代谢假说。此外，承包商将检查激素疗法(HT)如何改变代谢特征，以及这些变化是否解释了在妇女健康倡议(WHI)HT试验中观察到的联合HT风险增加的原因。